Intravesical oxybutynin: practicalities of clinical use.
Oral anticholinergic therapy, used for the treatment of detrusor overactivity (DO), is limited by systemic side-effects and because of failure to respond. Alternative routes of administration include the intravesical route. We reviewed 11 women who were treated with intravesical oxybutynin (IVO). All had idiopathic DO, their symptoms having been unsuccessfully controlled on oral agents. Seven patients had symptomatic improvement. Six out of the eight patients that completed their voiding diaries showed a reduction in voiding frequency. Five patients found the procedure too inconvenient. Seven patients suffered chemical irritation. One patient complained of voiding difficulties. No patient reported systemic side-effects. The mean duration of treatment was 4-5 weeks; two patients continue to use IVO. IVO can be used successfully in the treatment of DO, but its use is limited due to the inconvenience related to catheterisation. With the advent of Botox and oxybutynin patches, IVO probably has a limited role.
Guerrero
K
K
Department of Obstetrics and Gynaecology, Singleton Hospital, Swansea SA2 8QA, UK. karen.guerrero@swansea-tr.wales.nhs.uk
Emery
S
S
Owen
L
L
Rowlands
M
M
D000283:Administration, Intravesical; D018680:Cholinergic Antagonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage*; D017060:Patient Satisfaction; D012189:Retrospective Studies; D016896:Treatment Outcome; D014546:Urinary Catheterization; D014549:Urinary Incontinence / Q000188:drug therapy*
D018680:Cholinergic Antagonists; D008333:Mandelic Acids; C005419:oxybutynin